Sanofi Will Establish Lovenox Follow-On In Series Of Head-To-Head Trials
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi-Aventis is looking to establish its ultra low molecular weight heparin product AVE5026 - a follow-on to the firm's Lovenox - as more efficacious than enoxaparin in preventing venous thromboembolic events through a series of head-to-head trials against Lovenox